Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis

Bacteriophage (phage) therapy, which uses lytic viruses as antimicrobials, is a potential strategy to address the antimicrobial resistance (AMR) crisis. Cystic fibrosis (CF), a disease complicated by recurrent Pseudomonas aeruginosa pulmonary infections, is an example of AMR’s clinical impact. Using a novel personalized phage therapy strategy that selects phages for a predicted evolutionary ‘trade-off’, nine CF adults (8 female, 1 male) median age 32 (range 22-46) years were treated with phages on a compassionate basis because their clinical course was complicated by multi-drug resistant or pan-drug-resistant Pseudomonas that was refractory to prior courses of standard antibiotics. Individuals received nebulized cocktail or single phage therapy without adverse events. 5-18 days after phage therapy, sputum Pseudomonas decreased by a 104 CFU/mL median, or 102 CFU/mL mean difference (p = 0.006, Two-way ANOVA with Dunnett’s multiple comparisons test) without altering sputum microbiome, and ..., , , # Personalized Inhaled Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas aeruginosa in Cystic Fibrosis

[https://doi.org/10.5061/dryad.pc866t1t0](https://doi.org/10.5061/dryad.pc866t1t0)

## Description of the data and file structure

### Files and variables

Psa = *Pseudomonas aeruginosa*

Blanks = data not available

# File: Attachment.txt

**Description:** Percent attached cells for Psa isolates from patient 2 pre and post therapy

##### Variables

* Patient: subject numbers
* Pre: percent attached cells pre therapy
* Post: percent attached cells post therapy

#### File: CFU.txt

**Description:** CFU/ml  from 9 patients as measured from 10-fold serial dilutions of sputum in PBS plated on Pseudomonas isolation agar measured pre and post (14d vs 30d) therapy

##### Variables

* Patient: subject numbers
* Pre: CFU/ml (colony forming units per mL)  from 9 patients pre therapy
* Post(14d): CFU/ml (colony forming units per mL)  from 9 patients post therapy (14 days)
* ...